Ipilimumab price in 2023

Ipilimumab (Ipilimumab) is an anticancer drug commonly used to treat malignant melanoma (a type of skin cancer), especially in the treatment of advanced or metastatic melanoma. It is a type of immunotherapy drug, and its mechanism of action is to help the body fight cancer by enhancing the activity of the patient's own immune system.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug is priced around 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.

Ipilimumab is an antibody drug againstCTLA-4 (cytotoxicTlymphocyte antigen-4). CTLA-4 is a negative regulatory molecule that inhibits the activity of T cells, thereby reducing the aggressiveness of the immune system. By blocking the action of CTLA-4, ipilimumab enhances the activity of T cells, making them better able to attack cancer cells.

Although ipilimumab has shown good efficacy in some patients with malignant melanoma, it may cause some immune-related side effects, such as immune enteritis, immune thyroiditis, and skin reactions. Therefore, when using ipilimumab, patients need to be closely monitored and work with a medical professional to ensure effective treatment with the drug while minimizing the risk of side effects.

Please note that drug use and treatment options may vary depending on the individual condition, type of cancer, and clinician recommendations. Before using ipilimumab or any other drug, patients should discuss treatment options and risks in detail with their medical professional.